Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Geron
So what: The clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells will gauge its safety in patients. This is a milestone in possibly finding a cure for paralysis and a big step ahead of the competition for Geron.
Now what: This is the first step in a long road for Geron in clinical trials. The company has very little revenue and is spending about $10 million per quarter in cash flow, so the trial is critical for the company's long-term viability. Today's move is a reaction to great news, but there is a long ways to go for Geron. I would be cautious about buying on the bounce in this stock.
Interested in more info on Geron? Add it to your watchlist by clicking here.